MedTrace Logo

Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)

NCT01775124 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 332

Last updated 2019-09-04

Study results available
· View outcomes & findings →

Summary

The study evaluated the efficacy and safety of two different dosing regimens of ranibizumab (either monthly injections or injections as-needed based on the stability of a patient's vision) in Chinese patients with wet age-related macular degeneration (AMD) . This study was to provide long-term safety data in the treatment of Chinese patients with wet AMD.

Conditions

  • Neovascular Age-related Macular Degeneration

Interventions

DRUG

Ranibizumab

Intravitreal injections of 0.5 mg Ranibizumab

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-22
Primary Completion
2015-11-23
Completion
2015-11-23

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01775124 on ClinicalTrials.gov